Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Outlines Planned Adaptive Phase 2 Field Study of TNX-4800 for the Prevention of Lyme Disease, at the World Vaccine Congress Washington
Go back to Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Outlines Planned Adaptive Phase 2 Field Study of TNX-4800 for the Prevention of Lyme Disease, at the World Vaccine Congress Washington| TONIX PHARM HLDG (NASDAQ: TNXP) | Delayed: 11.96 -0.24 (1.97%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $12.20 | 52 Week High | $7.95 | |||
| Open | $11.79 | 52 Week Low | $0.40 | |||
| Day High | $12.58 | P/E | N/A | |||
| Day Low | $11.78 | EPS | $-5.33 | |||
| Volume | 466,811 | |||||
